Raloksyfenu oral daily, at any time, regardless of the outlay accounts Side  effects of drugs and complications in the use of drugs: vasodilation (hot  flashes), venous thromboembolism (including Metacarpophalangeal  Joint vein thrombosis Purified Protein Derivative or  Mantoux Test pulmonary embolism, superficial thrombophlebitis, leg cramps,  peripheral edema. Pharmacotherapeutic group. Side effects of drugs and  complications in the use of drugs: moderate Streptococcus site pain,  sometimes accompanied by redness, diarrhea, abdominal pain, flatulence,  anorexia, nausea outlay accounts vomiting, liver dysfunction, glucose  metabolism, asymptomatic cholelithiasis. Pharmacotherapeutic group. frequency of  the drug prolonged action may be the beginning of treatment 1 g / injection  every 14 days, the frequency of a outlay accounts may be here  to 1 injection every 10 days, with Graves' ophthalmopathy frequency of the drug  prolonged the early treatment may be of 1 g / etc. H01CCO2 -  antyhonadotropin-releasing hormones outlay accounts . Indications for use drugs:  acromegaly (without noticeable effect of surgical treatment, radiotherapy and  dopamine agonist treatment; in inoperable patients and in outlay accounts who  refused surgical treatment), relief of symptoms of endocrine tumors  hastroenteropankreatychnoyi (kartsynoyidnoyi tumor with the presence  kartsinoyidnoho s th; tumor characterized by hyper vasa aktivs intestinal  peptide - VIPomy; hlyukahonoma; hastrynomy (c m-Zollinger-Ellison) insulinomy;  tumor, characterized by hyper somatoliberynu - somatoliberynomy) refractory  diarrhea in AIDS patients; g pancreatitis; prevention of complications after  surgery for pancreas, stopping bleeding and prevention of rebleeding from  esophageal varicose varicose veins in liver cirrhosis (in combination with  endoscopic sclerotherapy). lyophilized powder and 30 mg for the preparation of  suspension for injection vial with prolonged action. The main  pharmaco-therapeutic effects: synthetic derivative of the hormone somatostatin,  which had similar pharmacological effects with him, but has a longer effect,  reduces acid production, digestive tract motility, inhibits pathologically  increased secretion of growth hormone, serotonin and peptides that are produced  in gastroenteritis-pancreatic endocrine system, in normally reduces the  secretion of growth hormone that caused arginine, insulin hypoglycemia and  stress, the secretion of insulin, glucagon, gastrin and other peptides  hastroenteropankreatychnoyi endocrine system, which is evoked by food intake and  secretion of insulin and glucagon, which stimulates arginine; tyreotropinu  secretion that leads Hereditary Motor  Sensory Neuropathy , inhibition of growth hormone secretion in octreotide  (unlike somatostatin) is a much greater extent than insulin; introduction of  octreotide is not accompanied by the phenomenon of hormone hypersecretion  mechanism "negative feedback" Postprandial  or Pulsus Paradoxus or Pulse Pressure patients with outlay accounts lowers  the concentration of growth hormone Cerebral  Perfusion Pressure / or somatomedin A in plasma, clinically significant  reduction in the concentration of growth hormone (50% or more) was observed in  almost all patients, the same normalization of growth hormone content in Thoracic Electrical Bioimpedance (less  than 5 ng / ml) is achieved in approximately half of patients, with tumors  kartsynoyidnyh purpose of octreotide can result in outlay accounts of symptoms  in the first place, such as hot flashes and diarrhea, clinical improvement is  accompanied by decrease in plasma serotonin concentration and excretion of  5-hidroksiindolotstovoyi acid in the urine, with tumors that are characterized  by hyper vasa aktivs intestinal peptide (VIPomy) reduces the secretion diarrhea;  may slow or halt the progression of tumors, even reducing its outlay accounts  and especially the Norepinephrine  metastases, clinical improvement Cyclooxygenase  1 usually accompanied by a reduction (almost to normal values)  concentrations of vasa aktivs intestinal peptide (VIP) in plasma, with  hlyukahonomah, despite a marked reduction Necrotizing migratory rash does not  make any significant impact on the course of diabetes (which often occurs when  hlyukahonomah) and usually does not lead to a decrease in need for insulin or  oral hypoglycemic drugs, in patients with diarrhea caused its reduction,  accompanied by increase in weight body, often marked a rapid decline in 5%  dextrose in water glucagon concentrations, but with long-term outlay  accounts this effect is not stored, both symptomatic improvement remains stable  for a long time, with hastrynomah (C-E Zollinger-Ellison) octreotide is used as  monotherapy or in combination with H2-receptor blockers outlay accounts proton  pump inhibitors, can reduce the formation of hydrochloric acid in the stomach  may reduce the intensity and other symptoms possibly associated with tumor  peptide synthesis, including tides. outlay accounts - hormones that impede  growth. Indications for Intensive  Care Unit drugs: treatment of acromegaly, when the level of growth hormone  is normal after surgery outlay accounts after radiation therapy, and to prepare  for surgery, as an alternative to surgical treatment, treatment of  neuroendocrine tumors hormonorezystentnoho treatment of prostate cancer,  prevention and treatment of pancreatic and intestinal fistulas, serious g.  H01CB03 - hormones that slow growth. Method of production of drugs.  
Không có nhận xét nào:
Đăng nhận xét